Theravance Biopharma, Inc.

NASDAQ:TBPH

Biotechnology

Healthcare
$17.03 -0.42%

-$0.07 today

Market cap
$882.64M
Beta
0.18
P/E (TTM)
7.4
EPS (TTM)
$2.23
52W Low $10.44High $21.03

Volume 10.02M

Average 0.43M

TBPH Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Theravance Biopharma, Inc.NASDAQ: TBPH

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $5.83M fell 49.1% year over year, behind the -21.6% change in trailing-twelve-month research & development. Sequentially, it fell 16.3% from the prior quarter. Over 3 fiscal years it compounded at -18.9% a year.

Context

  • Research & development amounted to 34.8% of revenue in FY2025, down 24.3 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -49.1% toward the trailing-twelve-month pace of -21.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.83M-16.3% QoQ
Last fiscal yearDec 2025
$37.41M-1.7% YoY
LTMMar 2026
$31.39M-21.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-49.1%——
1 year-1.7%——
3-year CAGR-18.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
37.41M USD
Year-over-year change
-1.7%
4-year CAGR
-34.4%

Research & Development vs competitors

How TBPH compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -21.6% is the 8th highest of 9, against a peer median of +8.9%.
  • Research & development amounts to 28.6% of revenue for TBPH, versus a peer median of 61.2%.
TBPH Competitors
Research & Development for TBPH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VIRVir Biotechnology, Inc.LTM Mar 2026$446.24M USD-15.0%-3.0%681.3%
REPLReplimune Group, Inc.LTM Dec 2025$223.39M USD+26.2%+32.9%—
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$153.38M USD+23.0%+18.5%357.1%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$129.68M USD+5.2%+71.4%—
TYRATyra Biosciences, Inc.LTM Mar 2026$111.3M USD+26.9%+33.8%—
VALNValneva SELTM Mar 2026€85.57M EUR+12.6%-6.7%54.7%
GERNGeron CorporationLTM Mar 2026$73.59M USD-17.7%-8.3%37.5%
TBPHTheravance Biopharma, Inc.LTM Mar 2026$31.39M USD-21.6%-18.9%28.6%
LENZLENZ Therapeutics, Inc.LTM Mar 2026$12.85M USD-48.8%-4.0%61.2%
Peer median (excluding TBPH) —+8.9%+7.7%61.2%

Competitors are the stored peer set for TBPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue55.31M51.35M57.42M64.38M107.46M
Cost of Revenue193.66M63.39M40.62M37.64M5.52M
Gross Profit(138.35M)(12.05M)16.8M26.74M101.95M
Gross Margin-250.1%-23.5%29.3%41.5%94.9%
Research & Development201.55M70.07M46.34M38.05M37.41M
Selling, General & Admin99.3M67.07M70.45M69.17M73.65M
Operating Expenses119.44M79.91M72.84M73.69M115.2M
Depreciation & Amortization4.81M3.04M2M3.62M5.52M
EBITDA(232.83M)(76.08M)(51.65M)(38.45M)137.22M
EBITDA Margin-420.9%-148.2%-89.9%-59.7%127.7%
Operating Income(257.78M)(91.96M)(56.04M)(46.95M)(13.25M)
Operating Margin-466.1%-179.1%-97.6%-72.9%-12.3%
Interest Income1.11M8.55M9.12M4.88M0
Interest Expense8.55M6.37M2.35M2.55M2.46M
Other Income / Expenses(7.44M)(858K)6.77M2.34M142.49M
Income Before Tax(265.22M)(92.82M)(49.27M)(44.61M)129.25M
Pre-Tax Margin-479.5%-180.8%-85.8%-69.3%120.3%
Income Tax Expense(151K)9K5.92M11.8M23.35M
Net Income(199.43M)872.13M(55.19M)(56.42M)105.9M
Net Margin-360.6%1698.5%-96.1%-87.6%98.5%
EPS (Basic)(2.87)(1.26)(1.00)(1.15)2.10
EPS (Diluted)(2.87)(1.26)(1.00)(1.15)2.06
Weighted Avg Shares69.46M73.59M55.3M48.85M50.32M
Weighted Avg Shares (Diluted)69.46M73.59M55.3M48.85M51.51M

Theravance Biopharma, Inc.

NASDAQ:TBPH

Intrinsic Alpha fair value

Locked

Current Price

$17.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.